Continued strong enrollment of pivotal Phase 3 global study evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 on track to complete enrollment by year end 2023
Company anticipates. -Today at 08:13 am- MarketScreener
Cyclo Therapeutics, Inc. , a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today.
Cyclo Therapeutics (CYTH) Reports Publication of Data from Phase 2 Study of Trappsol Cyclo streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
– Data published in official journal of Molecular Genetics and Metabolism Reports:
Evidence of a change in cholesterol homeostasis in peripheral organs and the brain after the initial infusion
Trappsol® Cyclo™ was detected in the CSF
Completers had an 88.9% improvement in at least two domains of the 17-Domain Niemann-Pick Type C1 Clinical Severity Scale (17D-NPC-CSS)
Improvement in Scale Assessment and Rating of Ataxia (SARA) score for the mean score in 7 of 8 domains at Week 48 compared with baseline
Demonstrated a favorable benefit-risk profile
Cyclo Therapeutics, Inc. , a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today. | June 12, 2023